Efficacy and safety of ixekizumab in psoriatic patients: a long-term real-world retrospective multicentre study from Southern Italy

This is a long-term retrospective multicentre study on adult patients with moderate to severe psoriasis in order to assess the long-term efficacy and safety of ixekizumab in a real-world setting. Our observation considered all patients who started treatment between 1 July 2017 and 31 December 2019, maintaining the treatment for at least 4 years. The majority of our cohort (52 patients; 74.3%) was between 260 and 312 weeks (6 years) under continuous treatment with ixekizumab. Our data confirm that ixekizumab may be considered a long-term effective and safe therapeutic option of moderate to severe plaque psoriasis.